|
Kazakhstan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Kazakhstan Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Kazakhstan .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Kazakhstani pharmaceutical and healthcare industry.
Competitive intelligence, Kazakhstani pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Kazakhstani market.
The Kazakhstan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Kazakhstan Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Kazakhstani pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Kazakhstan to test other views – a key input for successful budgeting and strategic business planning in the Kazakhstani pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Kazakhstani Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kazakhstan .
- Exploit The Latest Competitive Kazakhstani Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Kazakhstan .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Kazakhstan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - SWOT Analysis |
| Kazakhstan Political SWOT |
| Kazakhstan Economic SWOT |
| Kazakhstan Pharmaceuticals And Healthcare SWOT |
Chapter - Kazakhstan – Business Environment Ranking |
| Table: Central And Eastern Europe Pharmaceutical And Healthcare Business Environment Rankings |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Kazakhstan – Market Summary |
| Regulatory Regime |
| Intellectual Property Environment |
| Counterfeit Drugs |
| Pricing and Reimbursement Regime |
| Table: Price Components And Add-Ons For Imported And Locally Produced Generic Medicines (KZT) |
| Recent Pricing and Reimbursement Developments |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Table: Top 10 Manufacturers By Value Of Hospital Purchases |
| Table: Top 10 INNs By Value Of Hospital Purchases |
| Healthcare Sector Financing |
| Table: Top 10 ATC Groups By Value Of Hospital Purchases |
| Table: Top 10 ATC Groups By Retail Pharmacy Sales |
| Domestic Pharmaceutical Industry |
| Recent Domestic Industry Developments |
| Wholesale and Retail |
| Recent Wholesale and Retail Developments |
| Foreign Pharmaceutical Industry |
| Recent Foreign Industry Developments |
| Table: Pharmaniaga's Key Products |
| Clinical Trials |
| Medical Devices |
| Table: Medical Devices Market In Kazakhstan, 2006-2008 (US$mn) |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Kazakhstan's Drug Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Kazakhstan's Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Kazakhstan - Economic Activity |
| Prescription Market Forecast |
| Prescription Market Forecast |
| Table: Kazakhstan's Prescription Market Indicators, 2005-2013 (KZTmn unless otherwise stated) |
| OTC Market Forecast |
| Table: Kazakhstan's OTC Market Indicators, 2005-2013 (KZTmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Kazakhstan's Patented Drug Market Indicators, 2004-2013 |
| Generics Market Forecast |
| Table: Kazakhstan's Generics Market Indicators, 2004-2013 (KZTmn unless otherwise stated) |
| Export/Import Market Forecasts |
| Table: Kazakhstan's Pharmaceutical Trade Indicators, 2004-2013 (US$mn unless otherwise stated) |
| Table Retail Sales Structure Of Imports By Pharmaceutical Subgroups, 2006 |
| Table: Top 15 Distributors By Value Importing Pharmaceuticals Into Kazakhstan, 2006 |
| Table: Top 15 Distributors By Volume Importing Pharmaceuticals Into Kazakhstan, 2006 |
| Other Healthcare Data Forecasts |
| Table: Kazakhstan's Other Healthcare Data, 2004-2013 |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Top 10 Manufacturers By Retail Pharmacy Sales |
| Table: Top 10 Trade Names By Value Of Retail Pharmacy Sales |
Chapter - Company Monitor |
| Foreign Companies |
| Novartis (Lek & Sandoz) |
| Sanofi-Aventis |
| GlaxoSmithKline (GSK) |
| Nycomed |
| Merck & Co |
| Pfizer |
| Ranbaxy |
| Indigenous Companies |
| Chimpharm |
| Romat FK |
Chapter - Country Snapshot: Kazakhstan Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 1999-2004 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Kazakhstan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI has adjusted its forecast for the Kazakhstani pharmaceutical market for the period 2008 to 2013, reflecting a downgrade in our exchange-rate and economic growth forecasts over the period. The downgrade comes as the economy weathers the recent fall in commodities prices and the pressures of the global crisis. With a predicted compound annual growth rate (CAGR) of`9.04% over the forecast period, and total value reaching US$1.68bn in 2013, the pharmaceutical market will grow at a slower pace than in recent years . Kazakhstan retains huge potential as one of the least developed markets in Emerging Europe, with per-capita consumption only reaching US$96.0 in 2013. Meanwhile 2009 will likely see an 11.6% contraction in market value in US dollar terms, with 10.2% growth in local currency value.
The economic downturn should reverse by 2010. However, economic uncertainty and government intervention in the sector will slash growth rates for most players in 2009. Currency risks will remain acute and anti-crisis measures will hit margins. If the current bank bailout through the Samruk Kazyna state asset fund succeeds in stabilising the financial sector – until recently one of the most robust in the Commonwealth of Independent States (CIS) – this will improve confidence and operating conditions.
The Kazakhstani government has moved to control pharmaceutical prices following the tengue’s recent sharp fall against the US dollar. The February signing of the ‘Measures for Preserving the Stability of Medicines Provision’ between the government and pharmaceutical industry associations is designed to ensure supplies of medicines and limit price rises. The memorandum agreed to fix prices for 100 commonly used medicines but not already covered by free medical provision. Given the country’s overwhelming dependence on imports, price squeezes on retailers and wholesalers are likely to continue.
Health Minister Zhaksylyk Doskaliev announced measures to require distributors and pharmacies to reveal the price at which they purchased any particular medicines. Doskaliev also acknowledged that most medicines would go up in price, when he said in early March 2009 that a 15-25% increase in imported medicines prices was a ‘normal’ side effect of ‘market conditions’. Currency instability coincides with the April launch of its centralised drug procurement system for public hospitals. Manufacturers and suppliers will be under pressure to absorb price rises and local players like Chimpharm and Romat should benefit at the expense of foreign players.
With many companies racking up 20% to 30% local sales-growth rates in 2008, the rapid slowdown in the economy will slow growth plans. In February, the CFO of Hungary’s Egis, controlled by French giant Servier, said CIS growth forecasts for the company ranged between 0% and 15% due to economic uncertainty, especially in Kazakhstan. In one of the few signs of new investment projects, Indian and Kazakhstani leaders and trade officials signed a deal in March to create an Indian-Kazakhstani joint venture to produce pharmaceuticals, although few details of the project have been reported.
|
Kazakhstan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |